About · 08
An editorial console on the BPC-157 TB-500 record
What this project is, what the "doctor" in the name does and does not mean, and how the record is read.
What Wolverine Doctor is
Wolverine Doctor is a two-channel reading console for the peer-reviewed research on BPC-157 TB-500 — the two-peptide"Wolverine" blend. No clinic sits behind it and no clinician is on staff; it diagnoses no one and prescribes nothing. Nothing is made, sold, or shipped from here. Its whole work is reading published science and the public regulatory record and logging what they say.
The site is built as a research console: each finding is read against the constituent it belongs to — BPC-157 on one channel, TB-500 on the other — and the blend-level gaps are marked rather than smoothed over. Where the published record has no answer, the console says so.
What the "Doctor" in the name means
The "doctor" modifier in the domain name reads as a stance toward the literature, not a service on offer — a way of reading, not a thing on sale. It signals the register we read in: careful with mechanism, exact with doses-as-studied, and as rigorous with the FDA 503A and WADA record as with the science.
It is not a clinic, a physician, or a consultation service. There is no medical team behind this page, no prescriber, and no treatment offered. When we discuss the lawful compounded-access pathway on the Wolverine legal status and FDA 503A compounding access page, we describe the general regulatory landscape — never a route to obtain anything, and never advice.
How we handle the evidence
Two rules govern the content. First, every quantitative claim maps to a citation in the reference list — doses, half-lives, effect descriptions, and regulatory facts all carry a source. Second, the constituent-versus-blend distinction is never blurred: single-compound animal findings are labeled as such, and the absence of any controlled combination trial is stated plainly wherever the synergy question arises.
We also preserve the identity caveat that runs through the TB-500 literature — that most efficacy data attributed to it were generated with full-length Thymosin Beta-4, not the marketed heptapeptide [4]. The point of the console is to let a reader see exactly where each evidence point sits, and exactly where the record runs out.